IEH Corporation – Another Strong Beat; Increasing Target Price

To View the Complete Report

Author: Atrium Research November 13, 2026

Nicholas Cortellucci, CFA | Equity Research Analyst | [email protected] | 647-391-3314

Luca Perna | Equity Research Associate | [email protected] | 647-969-1027

PLEASE REVIEW THE DISCLOSURES AT THE BOTTOM OF THE PAGE

What you need to know:

  • Revenue came in at $10.7M (+51% YoY) and EBITDA of $1.3M (12% margin), beating our estimates of $9.9M and $0.8M, respectively.

  • Backlog reached a record $53.8M at quarter end (+192% YoY, +39% QoQ) and $56.0M as of the press release.

  • Gross margin came in at 28.3% in line with our 28.0% estimate, but declined compared to the high 33.1% reported in Q1.

  • We are updating our model to reflect the higher than expected growth and lower than expected G&A, resulting in an increased target price.

Yesterday, IEH Corporation (IEHC:OTCQX) reported its Q2 financials, which once again beat our estimates across the board. IEH demonstrated quality execution of its backlog, while continuing to build the backlog to new highs as its end markets are all growing. IEH remains one of our highest conviction names at the moment. We are maintaining our BUY rating and increasing our target price to $42.00/share (previously $38.00/share) on IEHC.

Q2 Financial Highlights

  • Revenue was $10.7M (+51% YoY), above our $9.9M estimate, bringing H1 revenue to $20.7M (+55% YoY). In Q2, defense revenue grew 71% YoY and medical revenue grew 373% YoY.

  • Revenue was comprised of 71% defense (vs. 62% in Q2/26), while commercial aerospace was 19% and other (medical) was a new high of 9%. This was partially offset by space revenue declining to just 1% of revenue due to the timing of a few key orders.

  • Backlog was $56M as of yesterday (+40% QoQ), the highest in the Company’s long history. Management continues to add equipment and personnel to service the rapidly growing demand. IEH does not foresee a change of course from the changes in Congress.

  • Gross margin was 28.3% vs. 22.9% in Q2/26, and in line with our 28.0% estimate. This was below the 33.1% reported in Q1, but reflects stress on its supply chain, higher gold prices, and freight costs.

  • SG&A was $1.8M (+15% YoY), largely due to higher sales commissions, growing at a much slower pace than revenue and highlighting the operating leverage in the business. Importantly, SG&A declined largely QoQ from the $2.4M in Q1 as SBC was nil.

  • EBITDA was $1.3M (12% margin) compared to our $0.8M estimate and $0.1M in Q2/26. The 12% margin compared to 9% in Q1/27 and 1% in Q2/26.

  • Net income was $1.4M or $0.55/share, compared to our $0.5M or $0.19/share estimate and a slight loss in Q2/26. This was supported by a $0.3M tax benefit.

  • Operating cash flow came in at $0.7M as A/R increased $1.2M QoQ and inventories increased $0.6M QoQ.

  • IEHC ended the quarter with $9.0M in cash plus $1.0M in restricted cash and total debt of $2.0M.

Figure 1: Q2 Financials Summary

Q2/27A Atrium Est. YoY
Revenue ($M) $10.7 $9.9 +51%
Gross Margin (%) 28% 28% +543 bps
EBITDA ($M) $1.3 $0.8 +1432%
EBITDA Margin (%) 12% 8% +1057 bps
Net Income ($M) $1.4 $0.5 N/A

To view the complete report, click on the button above.

Related posts

Subscribe to Newsletter

Subscribe VBNG Newsletter for news. Let's stay updated!